HEPHAISTOS-Pharma
Developing Tomorrow’s immuno-oncology and modulator therapy | A single platform for defeating cancer and much more.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €4.5m | Seed | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | (94 %) |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Hephaistos-Pharma is a preclinical stage biotech startup that is focused on developing advanced oncology treatments. Their primary goal is to enhance the effectiveness of immunotherapy, a treatment that uses the body's immune system to fight cancer. Currently, only 10% of patients see success with immunotherapy, and Hephaistos-Pharma aims to increase this percentage by stimulating the patient's immune response. They are working on turning 'cold' tumors, which are typically resistant to immunotherapy, into 'hot' targets that the immune system can easily attack.
The company operates in the biotech and healthcare market, serving patients suffering from incurable cancers. Their business model revolves around the research, development, and eventual commercialization of their innovative cancer treatments. They generate revenue through the successful development and sale of these treatments to healthcare providers.
Hephaistos-Pharma's team comprises experts in the field, including Professors Charles Dumontet and Jean-Yves Blay, both Key Opinion Leaders (KOLs) in oncology, Dr. Nathalie Garçon, a leading figure in vaccine development, and Dr. Olivier Favre-Bulle, a bio-engineering expert with extensive experience in the biotech industry.
One of their key innovations is ONCO-Boost, a first-in-class immunostimulant that can be injected intravenously to treat metastatic and hard-to-reach cancers like Osteosarcoma. The mechanism of action involves stimulating monocytes and dendritic cells, which are types of immune cells, to recruit and mature other immune defenses.
Keywords: Biotech, Oncology, Immunotherapy, Cancer Treatment, Cold Tumors, Hot Tumors, Preclinical Stage, Healthcare, Immunostimulant, Metastatic Cancer.